GLP-1 Injection Sites: Where to Inject, Rotation, Pain

Key takeaways

• Three sites, from the labels: the abdomen (2 inches from the navel), the front of the thigh, and the back of the upper arm, which the Zepbound label reserves for injections given by someone else.
• Rotate with every dose. Both labels require it; the Zepbound instructions name the reason (lipodystrophy and lumps), and in a survey of 430 insulin users 98 percent of those with lumps had not rotated correctly.
• The site does not change the dose. Both labels report similar exposure from abdomen, thigh and upper arm, and Wegovy's says the site and time of day can change without any dose adjustment.
• Injection-site reactions are common and mostly trivial: 1.4 percent of Wegovy patients versus 1 percent on placebo; 6 to 8 percent on Zepbound versus 2 percent, and 11.3 percent in the two-thirds of Zepbound patients who developed antibodies to the drug.
• Spreading redness, warmth, pus or fever, or hives and facial swelling, are not injection-site reactions. Call the same day.

GLP-1 injection sites are the same for every drug in the class and are printed on the labels: inject under the skin of the abdomen, the thigh, or the back of the upper arm, and rotate sites with each dose (Wegovy label) (Zepbound label). The time of day can change, the site can change, and neither requires a dose adjustment. That is the whole answer; the rest of this page is the detail that keeps the weekly shot painless and the skin intact. It is a companion to our microdosing GLP-1 guide, which covers what happens to the dose when people stray from the label, and to do GLP-1 patches work, for anyone hoping to avoid the needle altogether. The step-by-step technique, needle choice and sharps disposal are in how to inject peptides.

The three label sites

Sources: (Wegovy label) (Zepbound label). Two label sentences settle the question people most often ask, which is whether the site changes the result. The Wegovy pharmacokinetics section reads "Similar exposure was achieved with subcutaneous administration of semaglutide in the abdomen, thigh, or upper arm," and the Zepbound section says the same of tirzepatide; the Wegovy dosing section adds that "the time of day and the injection site can be changed without the need for a dosage modification" (Wegovy label) (Zepbound label). Pick the site for comfort and rotation, not for effect.

One practical note from the Wegovy instructions for use: if the pen does not start, or you have trouble injecting into the lower abdomen, the label suggests moving to a firmer site such as the thigh or upper arm, or standing up while injecting into the lower stomach (Wegovy label). Loose skin over a soft abdomen can make the pen's skin sensor fail to engage.

Rotation: what the labels require, and why

Both labels say to rotate injection sites with each dose. The Zepbound instructions are specific: you may use the same area of the body, but choose a different spot within it each week, never inject in the same site used for other medicines, and rotate "to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps)" (Zepbound label).

The evidence behind that warning comes from insulin, which is injected the same way far more often. In a survey of 430 insulin users, 64.4 percent had lipohypertrophy, the rubbery thickening of fat at overused sites; of those with lumps, 98 percent either did not rotate or rotated incorrectly, while only 5 percent of correct rotators had any, and reusing a needle more than five times raised the risk further (Blanco 2013). A 2026 international consensus puts prevalence at 29 to 76 percent of insulin users, names inadequate rotation as the strongest modifiable risk factor, and recommends systematic rotation plus a new needle for every injection; drug injected into a lump is absorbed unpredictably (Guo 2026). A weekly GLP-1 gives each site far more rest than daily insulin, which is why reactions are rarer, but the mechanism is identical and the fix is the same.

A four-week cycle that satisfies both labels:

Within a zone, move at least an inch from the previous spot. Note the date and site on your phone; four weeks later the first spot has rested a month. If you find a firm lump, skip that zone for a few months and tell your clinician.

Pen versus vial

Sources: (Wegovy label) (Zepbound label). The site rules do not change with the device; the measurement does. A pen's dose is the pen. A compounded vial's dose is units = mg ÷ mg per mL × 100, which is where the documented overdoses happened; the tirzepatide dosage chart has the units table and how many units are in 1 mL explains the syringe. For needle length, the international FITTER consensus concluded that 4 mm pen needles suit adults of any size and that the old 12.7 mm insulin needle should be avoided because it reaches muscle, especially in the thigh and in lean people (Frid 2016). One sterile needle and syringe per injection is the CDC rule and the lipohypertrophy consensus's second recommendation (CDC injection safety) (Guo 2026).

Injection-site reactions: the numbers from the labels

Sources: (Wegovy label) (Zepbound label). Two things follow. Tirzepatide produces more skin reactions than semaglutide in trial populations, and the label links that to antibodies, which nearly two-thirds of patients develop; the antibodies did not blunt the drug. And none of this covers compounded products, whose excipients, preservatives and impurities differ from the brand and have no comparable data.

Making the shot hurt less

• Room temperature. Take the pen or vial out of the refrigerator 15 to 30 minutes before. Cold solution stings.
• Dry skin. Let the alcohol evaporate completely; wet alcohol carried in on the needle is the usual cause of burning.
• Short, thin, fresh needle. 4 mm for a pen, 6 mm for a syringe, 31 gauge, used once (Frid 2016).
• Fast in, slow push, straight out. A quick insertion hurts less than a slow one; a slow injection stretches tissue less than a fast one.
• Press, do not rub. Both labels say to press lightly with gauze if blood appears and not to rub (Wegovy label) (Zepbound label). Rubbing bruises.
• Relax the area. A tense abdominal wall hurts; breathe out as you inject.
• Rotate. A rested site hurts less than a bruised one.

What is normal, and when to call

Normal, and needs nothing:

• A small bump, mild redness or itching that fades in a day or two
• A drop of blood, a small bruise
• Mild tenderness at the site for a day

Call your clinician the same day:

• Redness that spreads, warmth, swelling that grows, pus, or a fever: possible infection
• Hives, swelling of the face, lips or throat, wheezing or trouble breathing: possible allergic reaction, which both labels list as a serious hypersensitivity warning; call emergency services if breathing is affected (Wegovy label) (Zepbound label)
• A hard, painful lump lasting more than a few days, or lumps at several sites
• Any reaction at the site of a compounded product that you cannot explain, since its contents are unverified

Bottom line

Abdomen, thigh, or the back of the arm if someone else is injecting; 2 inches from the navel; a different spot every week; any time of day. The site does not change the dose or the effect, and the labels say so in one sentence each. What the site does change is comfort and skin: a short fresh needle, dry skin, room-temperature drug and real rotation make a weekly GLP-1 injection close to painless, and the lumps that come from skipping rotation are the one injection problem that takes months to undo.

Frequently asked questions

+−Where is the best place to inject GLP-1?

The Wegovy and Zepbound labels give three sites: the abdomen (at least 2 inches from the navel), the front of the thigh, and the back of the upper arm, which the Zepbound label reserves for injections given by another person. The labels say exposure was similar from all three, so none is more effective. Most people find the abdomen easiest and least painful; the thigh is the usual alternative. Rotate with every dose.

+−Where do you inject GLP-1 in the thigh?

The front or outer part of the middle third of the thigh, roughly a hand's width above the knee and below the hip crease, into the fat under the skin, not the muscle. Avoid the inner thigh. Lean people have less fat there, so lift a fold of skin with a longer needle or use the abdomen instead. Alternate legs, and move at least an inch from the last spot.

+−How do you inject tirzepatide in the stomach?

Choose a spot on the abdomen at least 2 inches from the belly button, away from the waistband, and away from any bruise, lump or scar. Clean it, let the alcohol dry, and hold the Zepbound pen flat against the skin or insert a short needle straight in. With the pen, press and hold the button for up to 10 seconds until you hear the second click; with a vial and syringe, inject slowly and leave the needle in for at least 5 seconds. Press, do not rub, and use a different spot next week.

+−Can I inject Wegovy or Zepbound in my arm by myself?

The labels list the back of the upper arm as a site, and the Zepbound label specifies that another person should give the injection there. The Wegovy instructions say the same: back of the upper arm only with help from someone else. It is hard to reach yourself without bunching the skin or injecting at the wrong depth. If you inject alone, use the abdomen or thigh.

+−Does the injection site change how well a GLP-1 works?

No. Both labels report that similar drug exposure was achieved with injection in the abdomen, thigh or upper arm, and the Wegovy label says the site and time of day can be changed without any dose adjustment. Site does matter for comfort and for avoiding lumps, which is why the labels require rotation, and a lump of thickened fat can absorb drug unpredictably if you keep injecting into it.

+−Why is there a lump, bruise or itchy spot where I injected?

A small bump, mild redness, itching or a bruise for a day or two is the normal injection-site reaction the labels describe: 1.4 percent of Wegovy patients and 6 to 8 percent of Zepbound patients reported one in the trials, mostly bruising, redness, itching, pain or rash. A firm, rubbery lump that persists is usually lipohypertrophy from injecting the same area repeatedly; skip it for a few months and rotate properly. Spreading redness, warmth, pus or fever means possible infection, and hives or swelling of the face means possible allergy: call the same day.

+−Do I still need to rotate sites with a once-weekly injection?

Yes. Both labels say to rotate injection sites with each dose, and the Zepbound instructions explain why: repeated injections in one spot can cause lipodystrophy (pits or thickened skin) and localized cutaneous amyloidosis (lumps). You can stay in the same area, such as the abdomen, as long as each week's spot is different; alternating sides of the abdomen and then thighs over a four-week cycle keeps every site rested for a month.

Sources

1. LabelNovo Nordisk. Wegovy (semaglutide) injection: prescribing information, revised June 2026, sections 2 (administration), 6 (injection site reactions, immunogenicity), 12.3 (similar exposure across sites) and the instructions for use (DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b). (2026)
2. LabelEli Lilly. Zepbound (tirzepatide) injection: prescribing information, revised August 2026, sections 2, 6, 12.3 and 12.6 and the instructions for use (DailyMed setid 487cd7e7-434c-4925-99fa-aa80b1cc776b). (2026)
3. GuidelineFrid AH et al. New insulin delivery recommendations (FITTER international consensus). Mayo Clin Proc 2016;91:1231-55. (2016)
4. StudyBlanco M et al. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab 2013;39:445-53. (2013)
5. GuidelineGuo L et al. Consensus recommendations on lipohypertrophy: insights from an international panel of experts. Diabetes Res Clin Pract 2026;239:113401. (2026)
6. GuidelineCDC. Injection safety: clinical safety guidance for healthcare providers. Reviewed March 2024. (2024)